fenofibrate has been researched along with orlistat in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Liberopoulos, EN; Tselepis, AD | 1 |
| Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Kostapanos, M; Liberopoulos, EN; Papavasiliou, EC; Tselepis, AD | 1 |
| Baulard, A; Daffé, M; Denis, O; Fontaine, V; Frita, R; Laval, F; Lefèvre, P; Rens, C; Wattiez, R | 1 |
| Bunjes, H; Roese, E | 1 |
| Augustijns, P; Braeckmans, M; Brouwers, J; Mols, R; Servais, C; Tack, J | 1 |
1 review(s) available for fenofibrate and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for fenofibrate and orlistat
| Article | Year |
|---|---|
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Lactones; Male; Metabolic Syndrome; Middle Aged; Obesity; Orlistat; Overweight | 2005 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss | 2006 |
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anti-Obesity Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Obesity; Orlistat; Overweight; Phospholipases A2; Risk Factors | 2007 |
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Topics: Anti-Obesity Agents; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Fenofibrate; Greece; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lactones; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Orlistat; Overweight | 2008 |
8 other study(ies) available for fenofibrate and orlistat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Fenofibrate; Hypolipidemic Agents; Lactones; Membrane Lipids; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium tuberculosis; Orlistat; Simvastatin; Vancomycin | 2016 |
Drug release studies from lipid nanoparticles in physiological media by a new DSC method.
Topics: alpha-Tocopherol; Animals; Blood; Calorimetry, Differential Scanning; Crystallization; Drug Carriers; Drug Liberation; Emulsions; Fenofibrate; Lactones; Nanoparticles; Orlistat; Rapeseed Oil; Swine; Triglycerides; Ubiquinone | 2017 |
Orlistat disposition in the human jejunum and the effect of lipolysis inhibition on bile salt concentrations and composition.
Topics: Bile Acids and Salts; Fenofibrate; Humans; Intestinal Absorption; Jejunum; Lipids; Lipolysis; Micelles; Orlistat | 2022 |